𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease

✍ Scribed by Dr. T. van Laar; C. Neef; M. Danhof; K. I. Roon; R. A. C. Roos


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
503 KB
Volume
11
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

A new formulation of a sublingual tablet with 10 mg apomorphine was examined in 13 patients with Parkinson's disease. Vitamin C (250 mg) was added sublingually to lower the salivary pH. Four patients received sublingual apomorphine and nine received sublingual apomorphine as well as vitamin C. Subcutaneous apomorphine was given to all patients. The study was designed as a randomized three‐way cross‐over study. T~max~, C~max~, and bioavailability (F) were determined. Clinical efficacy was assessed by hand‐tapping during 30 s, walking time over 25 m, and a 4‐point tremor score. The mean T~max~ after subcutaneous apomorphine was 14.5 ± 1.9 min with a mean C~max~ of 19.2 ± 3.8 ng/ml. The mean clearance of all paients was 3.8 ± 0.6 L/min. The mean T~max~ after sublingual apomorphine was 61.1 ± 6.9 min vs. 61.7 ± 8.2 min with vitmin C. The mean C~max~ was 7.4 ± 1.0 ng/ml (– vitamin C) vs. 4.3 ± 1.3 ng/ml (+ vitamin C). These data resulted consequently in a not significantly different mean biovailability, varying from 17.6% (– vitamin C) to 6.1% ( + vitamin C). The latency of onset of clinical efficacy varied between 25.0 ± 8.5 min ( – vitamin C) and 26.0 ± 5.3 min ( + vitamin C). The duration of effect was lower (not significantly) when vitamin C was added: 88.0 ± 12.5 min ( – vitamin C) vs. 61.0 ± 11.9 min ( + vitamin C). These data show that 10 mg apomorphine sublingually was effective in 56% of the patients. The combination with vitamin C did not significantly change the latency of noset or duration of clinical efficacy. Sublingual apomorphine should be considered as an alternative in the treatment of “off” ‐periods in Parkinson's disease, in particular when patients have the capacity to anticipate their off‐periods.


📜 SIMILAR VOLUMES


A novel sublingual apomorphine treatment
✍ William Ondo; Christine Hunter; Michael Almaguer; Joseph Jankovic 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB 👁 2 views

We tested a novel preparation of a sublingual apomorphine hydrochloride tablet (APO) in 10 patients with advanced Parkinson's disease complicated by motor fluctuations. After a dose titration, patients took either 40 mg APO three times per day alternating with levodopa doses (eight patients) or six

Apomorphine monotherapy in the treatment
✍ Alice J. Manson; Kirsten Turner; Andrew J. Lees 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB 👁 1 views

Continuous subcutaneous infusion of apomorphine is now increasingly recognized as an effective treatment for refractory off periods and peak-dose dyskinesias in Parkinson's disease. We have reviewed our experience with apomorphine infusions, after a strategy decision in 1995 based on emerging precli

Pharmacokinetics and clinical efficacy o
✍ Dr. T. van Laar; E. N. H. Jansen; C. Neef; M. Danhof; R. A. C. Roos 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 568 KB

## Abstract The pharmacokinetics and clinical effects of apomorphine after rectal administration were determined in five patients with idiopathic Parkinson's disease (PD). Three different pharmaceutical formulations were tested: a rectal solution of apomorphine (10 or 15 mg), a gelatin suppository

New delivery techniques in the drug trea
✍ W. Poewe 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 66 KB

A marked response to oral dopaminergic substitution is one of the diagnostic criteria for idiopathic Parkinson's disease. Oral L-Dopa treatment remains to be the most efficacious and best tolerated way of parkinsonian drug therapy. A majority of patients, however, will develop late complications inc

Melevodopa/carbidopa effervescent formul
✍ Fabrizio Stocchi; Mario Zappia; Valentina Dall'Armi; Jaime Kulisevsky; Paolo Lam 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 188 KB

## Abstract Melevodopa hydrochloride plus carbidopa in effervescent tablets (M/C) is a readily soluble antiparkinsonian tablet formulation. A total of 221 patients with Parkinson's disease and motor fluctuations entered a randomized, double‐blind, double‐dummy, controlled parallel group study, whic

Akathisia as a side effect of antipsycho
✍ Christian Prueter; Benedikt Habermeyer; Christine Norra; Christoph M. Kosinski 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 43 KB 👁 1 views

## Abstract Due to its low profile for extrapyramidal side‐effects, quetiapine has become an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson's disease (PD). We describe the case of a patient with PD who developed severe akathisia, a common complication